US patent granted for Therakind’s DriDose® multi-dose delivery system
Patent further strengthens Therakind’s extensive patent portfolio protecting its proprietary range of dry powder delivery devices
London, England – May 2024 – Therakind Limited (“Therakind”), a specialty pharmaceutical company focused on developing and delivering niche medicines for difficult-to-treat patient groups, today announces that the United States Patent and Trademark Office has granted a patent protecting the Company’s novel multi-dose, needle-free version of its dry powder nasal drug delivery system, DriDose®.
The utility patent protects the mechanism of dry powder delivery using DriDose’s unique delivery system. Therakind also has patents granted in China and Japan and pending in other major territories for the multi-dose version. The unit dose version of the DriDose® device has active patents in major territories including US, Europe, and China.
Dr Susan Conroy, CEO of Therakind, said: “We continue to build a strong intellectual property portfolio in key markets to protect our innovative dry power delivery systems. Our focus is to improve medical adherence and one of the key ways of doing this is to simplify the treatment regime with easier, simple-to-use delivery options. DriDose now includes single and multiple use, needle-free systems which allow for the right delivery route for both our own and partnered products.”
The DriDose® innovative dry powder nasal delivery device range is designed to incorporate various types of pharmaceutical candidates. The technology includes both single-use and reusable versions, each capable of being modified to accommodate different powder-loading capacities. The reusable device is designed to reduce plastic waste associated with single use devices and injections. The DriDose® device aims to simplify drug delivery and provide an alternative to nasal sprays, nebulizers, tablets, and injections. DriDose® technology has been validated in a clinical trial and tested with a range of molecules in both in vivo and in vitro settings.
Therakind has a pipeline of in-house and partnered DriDose® programmes in development and offers a proof-of concept programme for pharmaceutical companies interested in nasal drug administration. The programme utilises Therakind’s proprietary technologies and technical know-how to perform a feasibility study to derisk the programme prior to further development. For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
For more information, please contact:
Therakind Ltd
Dr Susan Conroy, Chief Executive Officer
Tel: ++44 (0) 208 346 603
Email: info@therakind.com
Website: www.therakind.com
About Therakind Limited
Therakind is a specialty pharmaceutical company with a proprietary and partnered pipeline focused on improving medicine adherence through more patient-friendly dosing options. We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to incorporate the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. To date, we have developed and obtained marketing authorisations for three products and our intranasal device for the delivery of a dry powder drug formulation, DriDose®, is available for co-development.
To find out more, please visit www.therakind.com